JP2024521105A5 - - Google Patents
Info
- Publication number
- JP2024521105A5 JP2024521105A5 JP2023571866A JP2023571866A JP2024521105A5 JP 2024521105 A5 JP2024521105 A5 JP 2024521105A5 JP 2023571866 A JP2023571866 A JP 2023571866A JP 2023571866 A JP2023571866 A JP 2023571866A JP 2024521105 A5 JP2024521105 A5 JP 2024521105A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192217P | 2021-05-24 | 2021-05-24 | |
| US63/192,217 | 2021-05-24 | ||
| PCT/EP2022/064061 WO2022248478A1 (en) | 2021-05-24 | 2022-05-24 | Compositions and methods for treating lung cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024521105A JP2024521105A (ja) | 2024-05-28 |
| JP2024521105A5 true JP2024521105A5 (https=) | 2025-06-03 |
| JPWO2022248478A5 JPWO2022248478A5 (https=) | 2025-06-03 |
Family
ID=82100132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571866A Pending JP2024521105A (ja) | 2021-05-24 | 2022-05-24 | 肺癌の処置用組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240254235A1 (https=) |
| EP (1) | EP4347038A1 (https=) |
| JP (1) | JP2024521105A (https=) |
| KR (1) | KR20240012413A (https=) |
| CN (1) | CN117425493A (https=) |
| AU (1) | AU2022281992A1 (https=) |
| BR (1) | BR112023023833A2 (https=) |
| CA (1) | CA3219960A1 (https=) |
| IL (1) | IL308530A (https=) |
| TW (1) | TW202313107A (https=) |
| WO (1) | WO2022248478A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120936347A (zh) * | 2023-04-14 | 2025-11-11 | 阿斯利康(瑞典)有限公司 | 非小细胞肺癌的治疗 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| US20190276543A1 (en) * | 2018-03-08 | 2019-09-12 | Astrazeneca Pharmaceuticals Lp | Compositions and methods for treating late stage lung cancer |
| BR112022022304A2 (pt) * | 2020-05-04 | 2022-12-20 | Merck Sharp & Dohme Llc | Métodos para tratar câncer usando uma combinação de um antagonista pd-1, uma quimiorradioterapia e um inibidor de parp |
-
2022
- 2022-05-24 CA CA3219960A patent/CA3219960A1/en active Pending
- 2022-05-24 WO PCT/EP2022/064061 patent/WO2022248478A1/en not_active Ceased
- 2022-05-24 BR BR112023023833A patent/BR112023023833A2/pt not_active Application Discontinuation
- 2022-05-24 TW TW111119315A patent/TW202313107A/zh unknown
- 2022-05-24 EP EP22731132.1A patent/EP4347038A1/en active Pending
- 2022-05-24 AU AU2022281992A patent/AU2022281992A1/en not_active Abandoned
- 2022-05-24 KR KR1020237041378A patent/KR20240012413A/ko active Pending
- 2022-05-24 CN CN202280037041.0A patent/CN117425493A/zh active Pending
- 2022-05-24 IL IL308530A patent/IL308530A/en unknown
- 2022-05-24 US US18/560,527 patent/US20240254235A1/en active Pending
- 2022-05-24 JP JP2023571866A patent/JP2024521105A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025002823A1 (es) | Sistema y método de refuerzo para torre de aerogenerador, y torre de aerogenerador. | |
| JP2024521105A5 (https=) | ||
| CL2025004051A1 (es) | Compuestos derivados de beta-carbolina y uso para inhibir la dihidroorotato deshidrogenasa. | |
| BR102022023461A2 (https=) | ||
| CN307046780S (https=) | ||
| BY13176U (https=) | ||
| BY13175U (https=) | ||
| BY13174U (https=) | ||
| BY13172U (https=) | ||
| BY13170U (https=) | ||
| BY13169U (https=) | ||
| BY13168U (https=) | ||
| BY13167U (https=) | ||
| BY13166U (https=) | ||
| BY13165U (https=) | ||
| BY13164U (https=) | ||
| BY13163U (https=) | ||
| BY13162U (https=) | ||
| BY13161U (https=) | ||
| BY13160U (https=) | ||
| CN307050035S (https=) | ||
| CN307048852S (https=) | ||
| BY13159U (https=) | ||
| CN307048718S (https=) | ||
| CN307048381S (https=) |